Circulation, Vol 81, 470-476, Copyright © 1990 by American Heart Association
DH Blankenhorn, P Alaupovic, E Wickham, HP Chin and SP Azen
A within-group risk factor analysis was conducted to predict angiographic
change in the Cholesterol Lowering Atherosclerosis Study, a randomized,
placebo-controlled trial of colestipol plus niacin therapy in men with
previous coronary bypass surgery. Global angiographic change, including
both native coronary arteries and bypass grafts after 2 treatment years,
was the end point. Risk factors included on-trial clinical measures, plasma
lipids, lipoproteins, and apolipoproteins. Univariate analysis indicated
that risk factors previously observed by others in epidemiologic
investigation of ischemic heart disease--total cholesterol, LDL
cholesterol, non-HDL cholesterol, triglycerides, apolipoprotein B, and
diastolic blood pressure--had significant effects in the placebo-treated
group. Univariate analysis indicated significant effects of apolipoprotein
C- III in drug- and placebo-treated groups. Multivariate analysis indicated
the predominant risk factor predicting the probability of global coronary
progression was non-HDL cholesterol in placebo-treated subjects and the
content of apolipoprotein C-III in high density lipoproteins of
drug-treated subjects. Both drug- and placebo-treated group findings point
to an important role for triglyceride-rich lipoproteins in progression and
regression of human atherosclerosis.
ARTICLES
Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts. Lipid and nonlipid factors
Department of Medicine and Preventive Medicine, University of Southern California, Los Angeles.
This article has been cited by other articles:
 |
|
 |
|
  J.-C. Fruchart, F. M Sacks, M. P Hermans, G. Assmann, W V. Brown, R. Ceska, M J. Chapman, P. M Dodson, P. Fioretto, H. N Ginsberg, et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients Diabetes and Vascular Disease Research, November 1, 2008; 5(4): 319 - 335. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Kulik, M. A. Brookhart, R. Levin, M. Ruel, D. H. Solomon, and N. K. Choudhry Impact of Statin Use on Outcomes After Coronary Artery Bypass Graft Surgery Circulation, October 28, 2008; 118(18): 1785 - 1792. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Movva and D. J. Rader Laboratory Assessment of HDL Heterogeneity and Function Clin. Chem., May 1, 2008; 54(5): 788 - 800. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lamon-Fava, D. M. Herrington, D. M. Reboussin, M. Sherman, K. V. Horvath, L. A. Cupples, C. White, S. Demissie, E. J. Schaefer, and B. F. Asztalos Plasma Levels of HDL Subpopulations and Remnant Lipoproteins Predict the Extent of Angiographically-Defined Coronary Artery Disease in Postmenopausal Women Arterioscler Thromb Vasc Biol, March 1, 2008; 28(3): 575 - 579. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kawakami, M. Aikawa, P. Libby, P. Alcaide, F. W. Luscinskas, and F. M. Sacks Apolipoprotein CIII in Apolipoprotein B Lipoproteins Enhances the Adhesion of Human Monocytic Cells to Endothelial Cells Circulation, February 7, 2006; 113(5): 691 - 700. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Olivieri, N. Martinelli, M. Sandri, A. Bassi, P. Guarini, E. Trabetti, F. Pizzolo, D. Girelli, S. Friso, P. F. Pignatti, et al. Apolipoprotein C-III, n-3 Polyunsaturated Fatty Acids, and "Insulin-Resistant" T-455C APOC3 Gene Polymorphism in Heart Disease Patients: Example of Gene-Diet Interaction Clin. Chem., February 1, 2005; 51(2): 360 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Cohn, C. Rodriguez, H. Jacques, M. Tremblay, and J. Davignon Storage of human plasma samples leads to alterations in the lipoprotein distribution of apoC-III and apoE J. Lipid Res., August 1, 2004; 45(8): 1572 - 1579. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Dallinga-Thie, I. I.L. Berk-Planken, A. H. Bootsma, and H. Jansen Atorvastatin Decreases Apolipoprotein C-III in Apolipoprotein B-Containing Lipoprotein and HDL in Type 2 Diabetes: A potential mechanism to lower plasma triglycerides Diabetes Care, June 1, 2004; 27(6): 1358 - 1364. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Olivieri, A. Bassi, C. Stranieri, E. Trabetti, N. Martinelli, F. Pizzolo, D. Girelli, S. Friso, P. F. Pignatti, and R. Corrocher Apolipoprotein C-III, metabolic syndrome, and risk of coronary artery disease J. Lipid Res., December 1, 2003; 44(12): 2374 - 2381. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W.-m. R. Wong, E. Hawe, L. K. Li, G. J. Miller, V. Nicaud, L. A. Pennacchio, S. E. Humphries, and P. J. Talmud Apolipoprotein AIV Gene Variant S347 Is Associated With Increased Risk of Coronary Heart Disease and Lower Plasma Apolipoprotein AIV Levels Circ. Res., May 16, 2003; 92(9): 969 - 975. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. R. Blackett, R. Germany, B. Sambo, and P. Alaupovic Apolipoprotein C-III Bound to Apolipoprotein B-containing Lipoproteins in Obese Girls Clin. Chem., February 1, 2003; 49(2): 303 - 306. [Full Text] [PDF]
|
|
|
|
|
|
H. N. Ginsberg New Perspectives on Atherogenesis: Role of Abnormal Triglyceride-Rich Lipoprotein Metabolism Circulation, October 15, 2002; 106(16): 2137 - 2142. [Full Text] [PDF]
|
|
|
|
|
|
K. K. Berneis and R. M. Krauss Metabolic origins and clinical significance of LDL heterogeneity J. Lipid Res., September 1, 2002; 43(9): 1363 - 1379. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Olivieri, C. Stranieri, A. Bassi, B. Zaia, D. Girelli, F. Pizzolo, E. Trabetti, S. Cheng, M. A. Grow, P. F. Pignatti, et al. ApoC-III gene polymorphisms and risk of coronary artery disease J. Lipid Res., September 1, 2002; 43(9): 1450 - 1457. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Ravnskov Is atherosclerosis caused by high cholesterol? QJM, June 1, 2002; 95(6): 397 - 403. [Full Text] [PDF]
|
|
|
|
|
|
H. Campos, D. Perlov, C. Khoo, and F. M. Sacks Distinct patterns of lipoproteins with apoB defined by presence of apoE or apoC-III in hypercholesterolemia and hypertriglyceridemia J. Lipid Res., August 1, 2001; 42(8): 1239 - 1249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Robins, D. Collins, J. T. Wittes, V. Papademetriou, P. C. Deedwania, E. J. Schaefer, J. R. McNamara, M. L. Kashyap, J. M. Hershman, L. F. Wexler, et al. Relation of Gemfibrozil Treatment and Lipid Levels With Major Coronary Events: VA-HIT: A Randomized Controlled Trial JAMA, March 28, 2001; 285(12): 1585 - 1591. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Bard, M. A. Charles, I. Juhan-Vague, P. Vague, P. Andre, M. Safar, J. C. Fruchart, E. Eschwege, and o. b. o. t. BIGPRO Study Group Accumulation of Triglyceride-Rich Lipoprotein in Subjects With Abdominal Obesity : The Biguanides and the Prevention of the Risk of Obesity (BIGPRO) 1 Study Arterioscler Thromb Vasc Biol, March 1, 2001; 21(3): 407 - 414. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. M. Sacks, P. Alaupovic, L. A. Moye, T. G. Cole, B. Sussex, M. J. Stampfer, M. A. Pfeffer, and E. Braunwald VLDL, Apolipoproteins B, CIII, and E, and Risk of Recurrent Coronary Events in the Cholesterol and Recurrent Events (CARE) Trial Circulation, October 17, 2000; 102(16): 1886 - 1892. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. N. Hodis Myocardial Ischemia and Lipoprotein Lipase Activity Circulation, October 3, 2000; 102(14): 1600 - 1601. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Oberman Hypertriglyceridemia and Coronary Heart Disease J. Clin. Endocrinol. Metab., June 1, 2000; 85(6): 2098 - 2105. [Full Text]
|
|
|
|
|
|
J. S. Cohn, C. Marcoux, and J. Davignon Detection, Quantification, and Characterization of Potentially Atherogenic Triglyceride-Rich Remnant Lipoproteins Arterioscler Thromb Vasc Biol, October 1, 1999; 19(10): 2474 - 2486. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. Harjai Potential New Cardiovascular Risk Factors: Left Ventricular Hypertrophy, Homocysteine, Lipoprotein(a), Triglycerides, Oxidative Stress, and Fibrinogen Ann Intern Med, September 7, 1999; 131(5): 376 - 386. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. N. Hodis Triglyceride-Rich Lipoprotein Remnant Particles and Risk of Atherosclerosis Circulation, June 8, 1999; 99(22): 2852 - 2854. [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Gotto Jr Prognostic and Therapeutic Significance of Low Levels of High-Density Lipoprotein Cholesterol: Current Perspectives Arch Intern Med, May 24, 1999; 159(10): 1038 - 1040. [Full Text] [PDF]
|
|
|
|
|
|
C. Khoo, H. Campos, H. Judge, and F. M. Sacks Effects of estrogenic oral contraceptives on the lipoprotein B particle system defined by apolipoproteins E and C-III content J. Lipid Res., February 1, 1999; 40(2): 202 - 212. [Abstract] [Full Text]
|
|
|
|
|
|
H. Jansen, G. Chu, C. Ehnholm, J. Dallongeville, V. Nicaud, and P. J. Talmud The T Allele of the Hepatic Lipase Promoter Variant C-480T Is Associated With Increased Fasting Lipids and HDL and Increased Preprandial and Postprandial LpCIII:B : European Atherosclerosis Research Study (EARS) II Arterioscler Thromb Vasc Biol, February 1, 1999; 19(2): 303 - 308. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Syvanne, M. S. Nieminen, M. H. Frick, H. Kauma, S. Majahalme, V. Virtanen, Y. A. Kesaniemi, A. Pasternack, C. Ehnholm, and M.-R. Taskinen Associations Between Lipoproteins and the Progression of Coronary and Vein-Graft Atherosclerosis in a Controlled Trial With Gemfibrozil in Men With Low Baseline Levels of HDL Cholesterol Circulation, November 10, 1998; 98(19): 1993 - 1999. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Dallongeville, J.-C. Fruchart, P. Maigret, S. Bertolini, G. Bittolo Bon, M. M. Campbell, M. Farnier, J. Langan, G. Mahla, P. Pauciullo, et al. Double-Blind Comparison of Apolipoprotein and Lipoprotein Particle Lowering Effects of Atorvastatin and Pravastatin Monotherapy in Patients With Primary Hypercholesterolemia Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1998; 3(2): 103 - 110. [Abstract] [PDF]
|
|
|
|
|
|
J. M. Gaziano, C. H. Hennekens, C. J. O'Donnell, J. L. Breslow, and J. E. Buring Fasting Triglycerides, High-Density Lipoprotein, and Risk of Myocardial Infarction Circulation, October 21, 1997; 96(8): 2520 - 2525. [Abstract] [Full Text]
|
|
|
|
|
|
M. H. Frick, M. Syvanne, M. S. Nieminen, H. Kauma, S. Majahalme, V. Virtanen, Y. A. Kesaniemi, A. Pasternack, and M.-R. Taskinen Prevention of the Angiographic Progression of Coronary and Vein-Graft Atherosclerosis by Gemfibrozil After Coronary Bypass Surgery in Men With Low Levels of HDL Cholesterol Circulation, October 7, 1997; 96(7): 2137 - 2143. [Abstract] [Full Text]
|
|
|
|
|
|
P. Alaupovic, W. J. Mack, C. Knight-Gibson, and H. N. Hodis The Role of Triglyceride-Rich Lipoprotein Families in the Progression of Atherosclerotic Lesions as Determined by Sequential Coronary Angiography From a Controlled Clinical Trial Arterioscler Thromb Vasc Biol, April 1, 1997; 17(4): 715 - 722. [Abstract] [Full Text]
|
|
|
|
|
|
E. C. Tozer and T. E. Carew Residence Time of Low-Density Lipoprotein in the Normal and Atherosclerotic Rabbit Aorta Circ. Res., February 1, 1997; 80(2): 208 - 218. [Abstract] [Full Text]
|
|
|
|
|
|
H. R. Superko Beyond LDL Cholesterol Reduction Circulation, November 15, 1996; 94(10): 2351 - 2354. [Full Text]
|
|
|
|
|
|
B. D. Miller, E. L. Alderman, W. L. Haskell, J. M. Fair, and R. M. Krauss Predominance of Dense Low-Density Lipoprotein Particles Predicts Angiographic Benefit of Therapy in the Stanford Coronary Risk Intervention Project Circulation, November 1, 1996; 94(9): 2146 - 2153. [Abstract] [Full Text]
|
|
|
|
|
|
J. W. Jukema, A. J. van Boven, B. Groenemeijer, A. H. Zwinderman, J. H.C. Reiber, A. V.G. Bruschke, J.A. Henneman, G.P. Molhoek, T. Bruin, H. Jansen, et al. The Asp9 Asn Mutation in the Lipoprotein Lipase Gene Is Associated With Increased Progression of Coronary Atherosclerosis Circulation, October 15, 1996; 94(8): 1913 - 1918. [Abstract] [Full Text]
|
|
|
|
|
|
W. J. Mack, R. M. Krauss, and H. N. Hodis Lipoprotein Subclasses in the Monitored Atherosclerosis Regression Study (MARS) : Treatment Effects and Relation to Coronary Angiographic Progression Arterioscler Thromb Vasc Biol, May 1, 1996; 16(5): 697 - 704. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. Senti, J. Pedro-Botet, J. Rubies-Prat, and F. Vidal-Barraquer Secondary Prevention of Coronary Heart Disease in Patients with Extracoronary Atherosclerosis: A Need for Accuracy of Low Density Lipoprotein Determination Angiology, March 1, 1996; 47(3): 241 - 246. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Cortellaro, D. Baldassarre, E. Cofrancesco, E. Tremoli, A. Colombo, C. Boschetti, and R. Paoletti Relation Between Hemostatic Variables and Increase of Common Carotid Intima-Media Thickness in Patients With Peripheral Arterial Disease Stroke, March 1, 1996; 27(3): 450 - 454. [Abstract] [Full Text]
|
|
|
|
|
|
J. Ferrieres, J. Lambert, S. Lussier-Cacan, and J. Davignon Coronary Artery Disease in Heterozygous Familial Hypercholesterolemia Patients With the Same LDL Receptor Gene Mutation Circulation, August 1, 1995; 92(3): 290 - 295. [Abstract] [Full Text]
|
|
|
|
|
|
A. M. Gotto Jr Lipid Lowering, Regression, and Coronary Events : A Review of the Interdisciplinary Council on Lipids and Cardiovascular Risk Intervention, Seventh Council Meeting Circulation, August 1, 1995; 92(3): 646 - 656. [Full Text]
|
|
|
|
|
|
B. G. Nordestgaard, R. Wootton, and B. Lewis Selective Retention of VLDL, IDL, and LDL in the Arterial Intima of Genetically Hyperlipidemic Rabbits In Vivo : Molecular Size as a Determinant of Fractional Loss From the Intima–Inner Media Arterioscler Thromb Vasc Biol, April 1, 1995; 15(4): 534 - 542. [Abstract] [Full Text]
|
|
|
|
|
|
D. H. Blankenhorn, R. L. Johnson, W. J. Mack, H. A. El Zein, and L. I. Vailas The Influence of Diet on the Appearance of New Lesions in Human Coronary Arteries JAMA, March 23, 1990; 263(12): 1646 - 1652. [Abstract] [PDF]
|
|